Gain Therapeutics
GANXGain Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for central nervous system disorders, lysosomal storage disorders, and metabolic diseases.
Earnings
Next report
Nov 11, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Gain Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for central nervous system disorders, lysosomal storage disorders, and metabolic diseases. The company utilizes its proprietary Magellan™ computational platform to identify allosteric binding sites on proteins, enabling the discovery of drugs that treat the underlying causes of disease through functional and conformational modulation.
Gain Therapeutics is a pioneer in allosteric drug discovery, leveraging a proprietary computational platform to target previously undruggable protein sites.
FAQ
- What is Gain Therapeutics's market cap?
- Gain Therapeutics (GANX) has a market capitalization of $75.1M and trades on NASDAQ.
- Who are Gain Therapeutics's competitors?
- Gain Therapeutics's key competitors include Schrödinger, Inc., Denali Therapeutics Inc., Prevail Therapeutics, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Gain Therapeutics have?
- Gain Therapeutics's subsidiaries include Gain Therapeutics SA.
- Where is Gain Therapeutics headquartered?
- Gain Therapeutics is headquartered in United States of America and employs approximately 32 people. It has been publicly traded since 2021.